Powerful Medicines: The Benefits, Risks, and Costs of Prescription DrugsIf you believe that the latest blockbuster medication is worth a premium price over your generic brand, or that doctors have access to all the information they need about a drug’s safety and effectiveness each time they write a prescription, Dr. Jerry Avorn has some sobering news. Drawing on more than twenty-five years of patient care, teaching, and research at Harvard Medical School, he shares his firsthand experience of the wide gap in our knowledge of the effectiveness of one medication as compared to another. In Powerful Medicines, he reminds us that every pill we take represents a delicate compromise between the promise of healing, the risk of side effects, and an increasingly daunting price. The stakes on each front grow higher every year as new drugs with impressive power, worrisome side effects, and troubling costs are introduced. This is a comprehensive behind-the-scenes look at issues that affect everyone: our shortage of data comparing the worth of similar drugs for the same condition; alarming lapses in the detection of lethal side effects; the underuse of life-saving medications; lavish marketing campaigns that influence what doctors prescribe; and the resulting upward spiral of costs that places vital drugs beyond the reach of many Americans. In this engagingly written book, Dr. Avorn asks questions that will interest every consumer: How can a product judged safe by the Food and Drug Administration turn out to have unexpectedly lethal side effects? Why has the nation’s drug bill been growing at nearly 20 percent per year? How can physicians and patients pick the best medication in its class? How do doctors actually make their prescribing decisions, and why do those decisions sometimes go wrong? Why do so many Americans suffer preventable illnesses and deaths that proper drug use could have averted? How can the nation gain control over its escalating drug budget without resorting to rationing or draconian governmental controls? Using clinical case histories taken from his own work as a practitioner, researcher, and advocate, Dr. Avorn demonstrates the impressive power of the well-conceived prescription as well as the debacles that can result when medications are misused. He describes an innovative program that employs the pharmaceutical industry’s own marketing techniques to reduce use of some of the most overprescribed and overpriced products. Powerful Medicines offers timely and practical advice on how the nation can improve its drug-approval process, and how patients can work with doctors to make sure their prescriptions are safe, effective, and as affordable as possible. This is a passionate and provocative call for action as well as a compelling work of clear-headed science. |
Contents
| 3 | |
BENEFITS | 21 |
THE PREGNANT MARES LESSON | 23 |
LEAVING THE DARK AGES BEHIND MOSTLY | 39 |
RISKS | 69 |
THE FAT IS IN THE FIRE | 71 |
TOO SWEET TO BE TRUE | 85 |
COLD COMFORT | 96 |
WHAT THE TRAFFIC WILL BEAR | 217 |
NAVIGATING THE THIRD DIMENSION | 235 |
INFORMATION | 267 |
SIGNALS NOISE AND THE BIG VOID | 269 |
INFORMATIONAL KUDZU | 292 |
DEVISING AN ANTIDOTE | 313 |
THE EMPERORS FASHION CRITICS | 339 |
SAME LANGUAGE DIFFERENT ACCENTS | 348 |
GETTING RISKS RIGHT | 102 |
THE MOST VULNERABLE PATIENTS | 126 |
ENTER DOCTOR FAUSTUS | 139 |
IMPERFECT MEASURES | 149 |
WHOSE RISK IS IT ANYWAY? | 160 |
A BALANCING ACT | 172 |
COSTS | 187 |
LIVE CHEAP OR DIE | 189 |
FILLING THE PIPELINE | 198 |
Other editions - View all
Powerful Medicines: The Benefits, Risks, and Costs of Prescription Drugs Jerry Avorn, M.D. No preview available - 2005 |
Common terms and phrases
academic detailing American analysis antibiotic anticoagulant approach approved asked assessment atrial fibrillation Avorn benefits better blood pressure cancer cause clinical trials cost cost-effectiveness coverage death decades decision developed diabetes doctors and patients dollars dose drug companies drug's economic elderly England Journal epidemiology estrogen evaluation evidence FDA's federal fen-phen fenfluramine funding given health care system heart attack heart disease HMOs hospital hypertension Journal of Medicine kind liver Lotronex manufacturers Medicaid medical school Medicare ment millions National older outcomes Parke-Davis percent pharmacoepidemiology pharmacology physicians pill placebo Powerful Medicines Premarin prescribing prescription drugs prevent problem quality-adjusted questions randomized trials reduce Redux reports Rezulin risk safety side effects streptokinase stroke therapy thiazides tion treat treatment Viagra Vioxx warfarin women